- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01474174
Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors
A Pilot Study of Influenza Vaccine Efficacy in Patients With Central Nervous System Tumors
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
PRIMARY OBJECTIVES:
I. The primary objective of this pilot study is to assess the efficacy of influenza vaccination in patients with central nervous system tumors as defined by a four-fold increase in hemagglutinin inhibition (HI) titers from the pre-vaccination baseline.
SECONDARY OBJECTIVES:
I. A secondary objective of this pilot study is to assess the efficacy of influenza vaccination in patients with central nervous system tumors as defined by a serum post-vaccination HI titer of at least 1:40.
II. The secondary objectives of this pilot study include an assessment of the relationship between a variety of clinical factors and seroconversion following influenza vaccination.
III. Subgroup analyses will include an investigation of seroconversion and treatment (actively receiving chemotherapy, radiation therapy or both), disease status (active treatment vs long term followup), and use and dose of glucocorticoids.
TERTIARY OBJECTIVES:
I. An additional area of interest which will be further explored in this pilot study is an assessment of the relationship between serologic markers of immune function and response to vaccination.
OUTLINE:
Patients receive trivalent influenza vaccine intramuscularly (IM) on day 0.
After completion of study treatment, patients are followed up at 14 days, 21 days, and 3 and/or 6 months.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
North Carolina
-
Winston-Salem, North Carolina, Förenta staterna, 27157
- Wake Forest University Health Sciences
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patients must have a clinical diagnosis of a primary central nervous system tumor
- Patients must be eligible to receive the influenza vaccine
- Patients must be able to provide written informed consent
Exclusion Criteria:
- Patients unable to receive the influenza vaccine due to history of allergy to egg proteins, allergy to influenza vaccine component, acute febrile illness at the time of proposed vaccine administration, history of clinically or virologically confirmed influenza infection in the previous 6 months, contraindication to intramuscular injections, Guillan-Barré syndrome, or other contraindication to the vaccine
- Patients who have received the 2011-2012 annual influenza vaccine prior to being considered for enrollment on this study
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Supportive care (vaccine therapy)
Patients receive trivalent influenza vaccine IM on day 0.
|
Korrelativa studier
Givet IM
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Efficacy of influenza vaccination in patients with central nervous system tumors as defined by a four-fold increase in HI titers from the pre-vaccination baseline
Tidsram: 6 months
|
Seroconversion rate will be defined as the percentage of patients with at least a four-fold increase in HI antibodies between baseline and follow up.
Seroprotection rate will be defined as the percentage of patients with a serum HI antibody of at least 1:40.
The relationship between seroconversion and various clinical variables including therapy status (active vs longterm follow-up), glucorticoid dose and immune function will be measured.
Seroconversion and seroprotection rate comparisons will be made to publish normative data for the general population.
|
6 months
|
Sekundära resultatmått
Resultatmått |
Tidsram |
---|---|
Efficacy of influenza vaccination in patients with central nervous system tumors as defined by a serum post-vaccination HI titer of at least 1:40
Tidsram: 6 months
|
6 months
|
Relationship between a variety of clinical factors and seroconversion following influenza vaccination
Tidsram: 6 months
|
6 months
|
Relationship between serologic markers of immune function and response to vaccination
Tidsram: 6 months
|
6 months
|
Samarbetspartners och utredare
Samarbetspartners
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- IRB00018422
- NCI-2011-03033 (Registeridentifierare: CTRP (Clinical Trial Reporting Program))
- CCCWFU 98411 (Annan identifierare: Wake Forest University Health Sciences)
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Neoplasma i centrala nervsystemet
-
London Health Sciences CentreAvslutadCentral venkateter Trombos | NeoplasmKanada
-
City of Hope Medical CenterPatient-Centered Outcomes Research Institute; National Cancer Institute...Aktiv, inte rekryterandeMalign fast neoplasma | Karcinom i matsmältningssystemet | Malignt kvinnligt reproduktionssystem Neoplasm | Genitourinary System CarcinomFörenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)AvslutadMalign fast neoplasma | Bröstkarcinom | Neoplasma i matsmältningssystemet | Hudkarcinom | Malignt kvinnligt reproduktionssystem Neoplasm | Metastatisk malign neoplasm av okänd primär | Malign Neoplasm i huvud och hals | Malign hjärnneoplasma | Malign neoplasma i centrala nervsystemet | Malign muskuloskeletal... och andra villkorFörenta staterna
-
Mayo ClinicNational Cancer Institute (NCI)RekryteringMalign fast neoplasma | Bröstkarcinom | Karcinom i matsmältningssystemet | Huvud- och halskarcinom | Hudkarcinom | Malignt kvinnligt reproduktionssystem Neoplasm | Malign hjärnneoplasma | Karcinom hos okänd primär | Karcinom i centrala nervsystemet | Genitourinary System Carcinom | Malign muskuloskeletal neoplasmFörenta staterna
-
City of Hope Medical CenterNational Cancer Institute (NCI)RekryteringBlåskarcinom | Njurkarcinom | Prostatakarcinom | Genitourinary System NeoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekryteringMalign fast neoplasma | Melanom | Kolit | Icke-småcelligt lungkarcinom | Malignt genitourinary system neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekryteringMelanom | Livmoderhalscancer | Bröstcancer | Diarre | Äggstockscancer | Lungcancer | Kolit | Livmodercancer | Malignt genitourinary system neoplasmFörenta staterna
-
National Cancer Institute (NCI)Aktiv, inte rekryterandeMalign fast neoplasma | Njurcellscancer | Clear Cell Renal Cell Carcinom | Steg III njurcellscancer AJCC v8 | Steg IV njurcellscancer AJCC v8 | Sarkomatoid njurcellscancer | Steg III Blåscancer AJCC v8 | Steg III njurbäckencancer AJCC v8 | Steg III Uretercancer AJCC v8 | Steg III Urethral Cancer AJCC v8 | Steg... och andra villkorFörenta staterna
-
National Cancer Institute (NCI)RekryteringSteg IV njurcellscancer AJCC v8 | Sarkomatoid njurcellscancer | Steg IV Blåscancer AJCC v8 | Steg IV Urethral Cancer AJCC v8 | Steg IVB prostatacancer AJCC v8 | Adenokarcinom i urinblåsan | Kromofob njurcellscancer | Papillärt njurcellscancer | Samlande kanalkarcinom | Klarcellsadenokarcinom i urinblåsan | Blåsa... och andra villkorFörenta staterna, Puerto Rico
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RekryteringMalign fast neoplasma | Kolit | Steg IVA lungcancer AJCC v8 | Steg IVB lungcancer AJCC v8 | Icke-småcelligt lungkarcinom | Steg III lungcancer AJCC v8 | Steg IV lungcancer AJCC v8 | Steg II lungcancer AJCC v8 | Steg IIA lungcancer AJCC v8 | Steg IIB lungcancer AJCC v8 | Steg IIIA lungcancer AJCC v8 | Steg IIIB... och andra villkorFörenta staterna
Kliniska prövningar på laboratoriebiomarköranalys
-
Recep Tayyip Erdogan University Training and Research...Hacettepe UniversityAvslutadAmputation | Diabetisk polyneuropatiKalkon
-
Liao Jian AnRekryteringHuvud- och halscancerTaiwan
-
Oregon Health and Science University4DMedicalAnmälan via inbjudanLungsjukdomar | KOL | Luftvägssjukdom | DyspnéFörenta staterna
-
Progenity, Inc.AvslutadDowns syndrom | Aneuploidi | DiGeorges syndrom | Turnersyndrom | Klinefelters syndrom | Kromosomradering | Edwards syndrom | Pataus syndromFörenta staterna
-
University of California, San FranciscoRekryteringFriska | Fertilitetsstörningar | Manlig infertilitet | Infertilitet, manligFörenta staterna
-
Modarres HospitalAvslutadKomplikationer | Bildvägledd biopsi | Njure GlomerulusIran, Islamiska republiken
-
Medwave Estudios LimitadaAsociación Chilena de SeguridadOkändYrkesmässig exponering | Muskuloskeletala sjukdomarChile
-
Healthy.io Ltd.Avslutad
-
Duke UniversityIndragenAntikoagulations- och trombostest (AT-POCT)Förenta staterna
-
Bandim Health ProjectResearch Center for Vitamins and Vaccines, Statens Serum InstituteAvslutadSpädbarnsdödlighet | BCGGuinea-Bissau